personalized medicine

Speeding Time to Market Cost-Effectively

September 27, 2011

With the recent news of pharma’s frustration with more price controls around the world, John Avellanet, frequent Biotech Blog poster and author of Get to Market Now!, is grinning right now for having predicting a strengthening of such price controls back in 2009 and in 2010.  Here is a brief interview with John, covering price [...]

Read the full article →

Profitability and Orphans: The Role of Price and Incentives in Four Different Markets

June 16, 2010

This is a student paper from the 2010 final projects in the NIH Foundation for Advanced Education in the Sciences’ TECH 366 — Biotechnology Management. The students were asked to tell a story based on the course lectures, and to expand with general lessons on biotechnology company management. Profitability and Orphans: The Role of Price [...]

Read the full article →

Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine

May 5, 2010

See larger image Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine (Paperback) By (author) John Avellanet List Price: $42.95 USD New From: $42.95 In Stock Used from: $29.95 In Stock Now available: a book by frequent BiotechBlog contributor, John Avellanet. In this new book — Get [...]

Read the full article →

Coming soon – Get to Market Now!

March 15, 2010

See larger image Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine (Paperback) By (author) John Avellanet List Price: $42.95 USD New From: $42.95 In Stock Used from: $29.95 In Stock Coming soon, a book by frequent BiotechBlog contributor, John Avellanet. In this new book — Get [...]

Read the full article →

Is the practice of medicine impeding medical innovation?

November 4, 2009

At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me to re-examine the question of whether the practice of medicine is capable of keeping pace with medical innovation. As mentioned in a previous post, the majority of patients receiving the personalized medicine drug Herceptin had [...]

Read the full article →

Pfizer’s Power on Individualized Medicine

September 15, 2009

In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s genome is sequenced and drug prescriptions are based on your genetic makeup, and argues that personalized medicine will be the defining paradigm for discovering and developing drugs of the future. To put these videos into [...]

Read the full article →